Sea Pines Rehabilitation Hospital in Melbourne, Florida, owned by Encompass Health and Holmes Regional Medical Center, was closed indefinitely due to severe flooding from heavy rains on Nov 1-2, 2026. All patients were safely evacuated, but the hospital sustained substantial damage. Encompass Health and its partner are committed to reopening and are evaluating options to refurbish or replace the facility. Despite closure expenses, Encompass Health reaffirmed its full-year 2026 financial guidance, highlighting Sea Pines' prior contribution to revenue and earnings.
Sea Pines Rehabilitation Hospital's indefinite closure due to flood damage is notable as 94 of 150 priced Health-sector US stocks on Pluang fell today. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 18:31 WIB: HIMS (Hims and Hers Health Inc) rose 7.52% to USD 25.87 with a typical hold time of 23 days and a Pluang order activity of 35% Sell / 65% Buy; GH (Guardant Health Inc. Common Stock) dropped 7.50% to USD 141.92 with a typical hold time of 9 days; ELAN (Elanco Animal Health Incorporated Common Stock) increased 6.80% to USD 25.28 with a typical hold time of 28 days.
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...
The Indonesia data center market is projected to grow from USD 2.08 billion in 2027 to USD 4.05 billion by 2032, at a CAGR of 14.28%. Growth is fueled by expanding hyperscaler cloud infrastructure, rising digital workloads, increasing demand for colo...
The S&P 500 Dividend Aristocrats, a group of 68 companies that have increased their dividends for at least 25 consecutive years, have recently outperformed the broader market. These stocks are favored by investors seeking steady and reliable dividend...
Emergent BioSolutions lowered its FY26 revenue and EBITDA guidance due to delays in government purchases and ongoing pricing pressure in the U.S. naloxone market. The company reported a sharp decline in gross margin and profitability, with adjusted E...
